California-based health tech company Prenuvo has announced the addition of several new diagnostic capabilities to its signature full-body MRI scans, expanding its preventative health offerings. The updates include testing for Type 2 diabetes risk, liver fat content, and body composition analysis. These enhancements are part of Prenuvo’s continued efforts to shift medical imaging toward proactive, early detection.
The expanded scan services aim to offer patients and healthcare providers a more detailed understanding of internal health markers without radiation or contrast agents. Prenuvo’s technology is designed to detect over 500 conditions, including various cancers and brain aneurysms, through a non-invasive procedure lasting about an hour.
The company also confirmed a new round of funding, though the exact amount has not been disclosed. This latest investment follows Prenuvo’s $70 million Series A round in 2023, led by investors including actress and wellness advocate Gwyneth Paltrow. The new funds will support the company’s national clinic expansion, with upcoming openings planned in Miami, Boston, and Seattle.
Founded in 2018, Prenuvo has been positioning itself as a leader in early-detection imaging, emphasizing a model that integrates advanced technology with a consumer-friendly healthcare experience. With growing demand for preventive health tools, the company’s latest developments signal an effort to further differentiate itself in the competitive medical imaging space.
